| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 |
Metropolis Healthcare
Metropolis Healthcare
2,014.60
-11.80
(-0.58%)
Market Cap
10,436.00 Cr
EPS
28.29
PE Ratio
68.52
Dividend Yield
0.00 %
Industry
Healthcare Services52 Week High
2,318.30
52 Week Low
1,315.00
PB Ratio
7.88
Debt to Equity
0.17
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Metropolis Healthcare Limited has completed the acquisition of Dr. RS Patil's Ambika Pathology Laboratory, a sole proprietorship firm owned by Dr. Rajendra Sadashiv Patil. The acquisition became effective September 18, 2025, and was executed as a going concern under the terms of a Business Transfer Agreement. Operations of Ambika Pathology are now being conducted under Metropolis Healthcare Limited. The acquisition includes deferred consideration terms as outlined in the Business Transfer Agreement.
Metropolis Healthcare Limited incorporated a wholly owned subsidiary named Metropolis Quality Solutions Private Limited on September 15, 2025. The new entity operates in the healthcare technology sector and will develop and deal in technology-driven products and services in the healthcare sector. Metropolis Healthcare subscribed to 10,000 equity shares of face value INR 10 each through initial capital subscription in cash, maintaining 100% shareholding. The subsidiary is incorporated under the Indian Companies Act, 2013, with CIN U74909MH2025PTC457187 and registered office in Maharashtra.
Metropolis Healthcare Reports 23% Revenue Growth in Q1 FY26, Driven by Organic Growth and AcquisitionsAug 14, 2025
Metropolis Healthcare Limited reported 23% revenue growth for Q1 FY26, with organic business growing 13.2% driven by volumes and improved realizations. The company achieved 24.7% EBITDA margin on organic basis, up 40 basis points sequentially. Patient volumes grew 7% organically to 3.2 million, while B2C revenue increased 16% year-on-year. The company is integrating three recent acquisitions - Core Diagnostics, DAPIC Dehradun, and Scientific Pathology Agra. Core Diagnostics turned EBITDA positive with low single-digit margins, improving from breakeven levels. Metropolis announced acquisition of Ambika Diagnostics in Kolhapur for Rs.17 crores. The company expanded basic radiology services to 20 locations with full services and 240 locations offering ECG. TruHealth preventive portfolio now contributes 18% of overall revenue, growing 22% year-on-year. North region contribution increased to 17% of total revenue, largely due to Core Diagnostics integration. The company added 80 new collection centers in Q1 and plans to add 400+ centers this year, expanding presence from 750 to 1,000 towns.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,194.50 | #1 26,762.10 | 52.17 | #1 2,554.80 | 11.28 | #1 492 | 24.30 | 48.34 | |
1,019.90 | 10,473.10 | 69.35 | 699.70 | 23.06 | 144 | 22.54 | 46.31 | |
2,014.60 | #3 10,436.00 | #8 68.52 | #2 1,346.30 | #9 10.64 | #2 146 | #6 18.90 | 43.26 | |
1,124.20 | 5,957.60 | 55.86 | 702.20 | 20.80 | 91 | 60.25 | 39.98 | |
793.35 | 2,561.70 | 31.98 | 742.70 | 16.70 | 78 | 14.53 | 44.10 | |
298.00 | 1,552.00 | 46.65 | 255.90 | 15.11 | 31 | 19.48 | 48.47 | |
1,364.00 | 1,170.70 | 23.87 | 111.60 | 28.72 | 48 | 11.50 | 40.60 | |
313.20 | 996.30 | #1 10.83 | 1,170.80 | -18.47 | -134 | -35.12 | 57.31 | |
276.00 | 537.40 | 20.39 | 147.80 | #1 134.60 | 19 | #1 444.44 | 59.70 | |
189.90 | 132.30 | 88.74 | 41.80 | 13.28 | 2 | 0.00 | 42.17 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,078 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2021 |  Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 17 Nov 2023 | Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,055.70 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,092.90 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Updates on Acquisition9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-AcquisitionSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Update On Schedule Of Earnings Conference Call For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for The Meeting Held Today (August 07 2025)Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2025
Jul 08, 2025Business Update For Q1FY26Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 18, 2025
Jun 18, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 18 2025Jun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Jun 17, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 16, 2025
Jun 16, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 03 2025Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 24, 2025
May 24, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
May 19, 2025Technical Indicators
RSI(14)
Neutral 42.21
ATR(14)
Less Volatile 68.59
STOCH(9,6)
Neutral 50.93
STOCH RSI(14)
Neutral 24.86
MACD(12,26)
Bearish -14.57
ADX(14)
Strong Trend 26.54
UO(9)
Bearish 46.47
ROC(12)
Downtrend And Accelerating -6.45
WillR(14)
Neutral -61.32
Mutual Fund Holdings
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth 
Tata Balanced Advantage Fund Direct - Growth 
Kotak Balanced Advantage Fund Direct - Growth 
JM Small Cap Fund Direct - Growth 
UTI Dividend Yield Fund Direct-Growth 
Templeton India Value Fund Direct Plan-Growth 
Bandhan Small Cap Fund Direct-Growth 
NJ ELSS Tax Saver Scheme Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
ITI Bharat Consumption Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
13 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
